http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20110135018-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5351c62aee4203f2be2944f21a6def2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3823072e9e783abee1108a6c93bf540 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a0d4d262c1b79943eb541fc23721931 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2149a719bdf620d7f8201917c474c7d3 |
| publicationDate | 2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20110135018-A |
| titleOfInvention | Pharmaceutical compositions for the treatment or prevention of cancer |
| abstract | The present invention provides a pharmaceutical composition for the treatment or prevention of cancer, comprising a pharmaceutically acceptable carrier and a compound of formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient, the preparation of a medicament for the treatment or prevention of cancer A method of treating or preventing cancer comprising administering to a subject a use of a compound of formula 1 and a therapeutically effective amount of a compound of formula 1. The present invention also provides a combination formulation comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof and a second drug. The compound of formula 1 according to the present invention is a substance that inhibits the Wnt / β-catenin signaling system and modulates the Ras protein stability, and shows resistance to various anticancer agents including antibody anticancer agents against EGFR, VEGF, etc. due to the mutation of ras gene. Can effectively treat patients. [Formula 1] |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015065518-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10426774-B2 |
| priorityDate | 2010-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 218.